A combination of rapamycin and resveratrol tested in an animal model was able to specifically inhibit the PI3K/Akt/mTORC1 signaling pathway, activating apoptosis and reducing cell survival in a TSC2-/- xenograft tumor model of LAM but not in cells expressing TSC2 (Alayev et al., 2015). Here, TSC2 is linked to lymphangioleiomyomatosis.